Key Indicators of Value & Success in a Life Science Company: What Investors Look For

Venture Capital and strategic investors value new and emerging life science companies differently in these challenging times. Entrepreneurs have been forced to modify business plans to stay afloat, while investors have taken a different approach to determining a life science company’s value.

This session will cover long-term strategies that emerging life science businesses should consider when seeking investors, while highlighting opportunities for investors in discovering and creating sustainable value.

• Diverse perspectives from angel investors to mid-tier funds
• Issues and perspective from the entrepreneur’s view
• State of the venture and strategic markets and current trends
• Factors to be considered in determining the investment opportunities and future returns of life science companies
• The role of IP in value creation
• Understanding market opportunities and constraints

Panelists:

• Gabor Garai, Partner, Foley & Lardner LLP
• Patrick Heron, General Partner, Frazier Healthcare Ventures
• Jay S. Kunin, Ph.D., Vice President, TechCoast Angels
• Bill Molloie, Partner, San Diego Life Sciences Lead, Pricewaterhouse Coopers
• Hans Petersen, CEO, Traversa Therapeutics